X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7109) 7109
Book Review (1018) 1018
Publication (362) 362
Conference Proceeding (11) 11
Book Chapter (8) 8
Magazine Article (6) 6
Book / eBook (5) 5
Dissertation (5) 5
Data Set (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (6661) 6661
index medicus (6550) 6550
female (4348) 4348
male (4294) 4294
antimetabolites, antineoplastic - adverse effects (4089) 4089
middle aged (3553) 3553
aged (3286) 3286
oncology (3148) 3148
antimetabolites, antineoplastic - therapeutic use (3034) 3034
antimetabolites, antineoplastic - administration & dosage (2954) 2954
adult (2561) 2561
chemotherapy (2188) 2188
deoxycytidine - analogs & derivatives (2017) 2017
treatment outcome (1718) 1718
cancer (1706) 1706
fluorouracil - adverse effects (1370) 1370
antineoplastic combined chemotherapy protocols - therapeutic use (1329) 1329
deoxycytidine - adverse effects (1282) 1282
fluorouracil - administration & dosage (1163) 1163
pharmacology & pharmacy (1077) 1077
aged, 80 and over (1064) 1064
5-fluorouracil (1056) 1056
deoxycytidine - therapeutic use (1000) 1000
antineoplastic combined chemotherapy protocols - adverse effects (967) 967
deoxycytidine - administration & dosage (963) 963
fluorouracil - therapeutic use (934) 934
capecitabine (887) 887
therapy (882) 882
gemcitabine (869) 869
drug administration schedule (853) 853
fluorouracil (836) 836
animals (764) 764
medicine & public health (715) 715
hematology (690) 690
fluorouracil - analogs & derivatives (684) 684
methotrexate - adverse effects (684) 684
care and treatment (675) 675
retrospective studies (636) 636
methotrexate (633) 633
toxicity (614) 614
survival analysis (605) 605
disease-free survival (588) 588
carcinoma (578) 578
adenocarcinoma - drug therapy (572) 572
adolescent (567) 567
colorectal neoplasms - drug therapy (563) 563
pancreatic neoplasms - drug therapy (544) 544
survival rate (543) 543
dose-response relationship, drug (538) 538
antimetabolites, antineoplastic - pharmacology (535) 535
neoplasm staging (529) 529
trial (525) 525
combined modality therapy (523) 523
drug combinations (522) 522
methotrexate - administration & dosage (504) 504
antimetabolites, antineoplastic - pharmacokinetics (494) 494
child (486) 486
survival (473) 473
infusions, intravenous (467) 467
research (462) 462
prognosis (450) 450
cisplatin (445) 445
breast neoplasms - drug therapy (442) 442
abridged index medicus (439) 439
radiotherapy (436) 436
neoplasms - drug therapy (425) 425
lung neoplasms - drug therapy (422) 422
antineoplastic agents (413) 413
time factors (410) 410
analysis (406) 406
administration, oral (403) 403
chemotherapy, adjuvant (400) 400
prospective studies (397) 397
follow-up studies (396) 396
surgery (395) 395
risk factors (392) 392
colorectal cancer (384) 384
antineoplastic combined chemotherapy protocols - administration & dosage (378) 378
antimitotic agents (370) 370
drug therapy (368) 368
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (365) 365
pancreatic cancer (363) 363
antineoplastic agents - adverse effects (357) 357
phase-ii (345) 345
remission induction (344) 344
stomach neoplasms - drug therapy (341) 341
child, preschool (339) 339
disease progression (338) 338
hematology, oncology and palliative medicine (335) 335
pharmacology/toxicology (334) 334
tegafur - administration & dosage (330) 330
leucovorin (328) 328
cisplatin - administration & dosage (321) 321
leukemia (321) 321
health aspects (320) 320
mice (320) 320
leucovorin - administration & dosage (313) 313
tegafur - adverse effects (313) 313
antineoplastic agents - administration & dosage (307) 307
antineoplastic agents - therapeutic use (299) 299
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6383) 6383
Japanese (324) 324
French (124) 124
German (80) 80
Chinese (54) 54
Spanish (48) 48
Russian (31) 31
Italian (20) 20
Dutch (12) 12
Polish (9) 9
Danish (8) 8
Hungarian (8) 8
Portuguese (5) 5
Finnish (3) 3
Norwegian (3) 3
Bulgarian (2) 2
Hebrew (2) 2
Korean (2) 2
Lithuanian (2) 2
Turkish (2) 2
Czech (1) 1
Romanian (1) 1
Serbian (1) 1
Swedish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 05/2014, Volume 123, Issue 21, pp. 3239 - 3246
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10073, pp. 1011 - 1024
Summary Background The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than adjuvant... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | THERAPY | ADENOCARCINOMA | CHEMORADIOTHERAPY | FOLINIC ACID | MODEL | CHEMOTHERAPY | Capecitabine - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Carcinoma, Pancreatic Ductal - surgery | Antimetabolites, Antineoplastic - administration & dosage | Pancreatic Neoplasms - drug therapy | Aged, 80 and over | Adult | Carcinoma, Pancreatic Ductal - mortality | Deoxycytidine - adverse effects | Female | Pancreatic Neoplasms - mortality | Chemotherapy, Adjuvant | Deoxycytidine - administration & dosage | Pancreatic Neoplasms - surgery | Kaplan-Meier Estimate | Treatment Outcome | Carcinoma, Pancreatic Ductal - drug therapy | Capecitabine - adverse effects | Antimetabolites, Antineoplastic - adverse effects | Aged | Deoxycytidine - analogs & derivatives | Antimitotic agents | Cancer patients | Care and treatment | Pancreatic cancer | Clinical trials | Product development | Metastasis | Comparative analysis | Antineoplastic agents | Studies | Antigens | Chemotherapy | Acids | Pragmatism | Pharmaceutical industry | Cancer therapies | Abdomen | Index Medicus | Abridged Index Medicus | Clinical Medicine | Medical and Health Sciences | Cancer and Oncology | Klinisk medicin | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2013, Volume 369, Issue 18, pp. 1691 - 1703
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2013, Volume 31, Issue 23, pp. 2895 - 2902
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2008, Volume 9, Issue 3, pp. 215 - 221
Journal Article
Annals of Oncology, ISSN 0923-7534, 11/2012, Volume 23, Issue 11, pp. 2799 - 2805
Sorafenib is an oral anticancer agent targeting Ras-dependent signaling and angiogenic pathways. A phase I trial demonstrated that the combination of... 
Advanced pancreatic cancer | Gemcitabine | Sorafenib | Phase III randomized trial | MULTICENTER | MONOTHERAPY | sorafenib | SOLID TUMORS | BEVACIZUMAB | ADENOCARCINOMA | BRAF INHIBITORS | COMBINATION | RAF/MEK/ERK PATHWAY | CHEMOTHERAPY | phase III randomized trial | ONCOLOGY | gemcitabine | ONCOLOGY GROUP | advanced pancreatic cancer | Niacinamide - analogs & derivatives | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Antimetabolites, Antineoplastic - administration & dosage | Pancreatic Neoplasms - drug therapy | Deoxycytidine - therapeutic use | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Aged, 80 and over | Placebos | Adult | Deoxycytidine - adverse effects | Female | Double-Blind Method | Deoxycytidine - administration & dosage | Niacinamide - adverse effects | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Niacinamide - administration & dosage | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Antimetabolites, Antineoplastic - therapeutic use | Phenylurea Compounds - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Ribonucleotide Reductases - antagonists & inhibitors | Antimetabolites, Antineoplastic - adverse effects | Aged | Deoxycytidine - analogs & derivatives | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2009, Volume 360, Issue 20, pp. 2055 - 2065
This trial compared standard multiagent chemotherapy with a single agent (capecitabine) as adjuvant therapy for breast cancer in women 65 years of age or... 
SURVIVAL | TRIAL | MEDICINE, GENERAL & INTERNAL | THERAPY | CYCLOPHOSPHAMIDE | DOXORUBICIN | FOLLOW-UP | PHASE-II | DOSE-INTENSITY | CONSENSUS RECOMMENDATIONS | AGE | Breast Neoplasms - surgery | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Capecitabine | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Receptors, Estrogen - analysis | Methotrexate - therapeutic use | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Cisplatin - administration & dosage | Fluorouracil - therapeutic use | Deoxycytidine - therapeutic use | Neoplasm Metastasis | Fluorouracil - administration & dosage | Fluorouracil - adverse effects | Chemotherapy, Adjuvant - adverse effects | Aged, 80 and over | Deoxycytidine - adverse effects | Female | Doxorubicin - administration & dosage | Fluorouracil - analogs & derivatives | Kaplan-Meier Estimate | Neoplasm Recurrence, Local | Breast Neoplasms - drug therapy | Methotrexate - adverse effects | Antimetabolites, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Antimetabolites, Antineoplastic - adverse effects | Survival Analysis | Methotrexate - administration & dosage | Aged | Neoplasm Staging | Deoxycytidine - analogs & derivatives | Evaluation | Care and treatment | Usage | Aged women | Adjuvant treatment | Breast cancer | Comparative analysis | Health aspects | Cancer | Chemotherapy | Toxicity | Leukemia | Age | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2011, Volume 364, Issue 19, pp. 1817 - 1825
In this study, a four-drug combination chemotherapy regimen was associated with objective responses in more than 30% of patients and increased survival by more... 
PHASE-III TRIAL | 5-FLUOROURACIL | MEDICINE, GENERAL & INTERNAL | SOLID TUMORS | CLINICAL-TRIALS | IRINOTECAN | OXALIPLATIN | 1ST-LINE THERAPY | COMBINATION | CARCINOMA | COOPERATIVE-ONCOLOGY-GROUP | Leucovorin - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Pancreatic Neoplasms - drug therapy | Deoxycytidine - therapeutic use | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Neoplasm Metastasis - drug therapy | Adult | Camptothecin - administration & dosage | Deoxycytidine - adverse effects | Female | Pancreatic Neoplasms - mortality | Camptothecin - analogs & derivatives | Severity of Illness Index | Pancreatic Neoplasms - pathology | Proportional Hazards Models | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Antimetabolites, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Survival Analysis | Quality of Life | Aged | Deoxycytidine - analogs & derivatives | Adenocarcinoma - mortality | Chemotherapy, Combination | Usage | Care and treatment | Gemcitabine | Pancreatic cancer | Leucovorin | Comparative analysis | Drug therapy | Fluorouracil | Clinical trials | Cytotoxicity | Pancreas | Patients | Index Medicus | Abridged Index Medicus
Journal Article